



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

18th July 2026

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub: Intimation of Board Meeting to consider Unaudited Financial Results of the Company for the quarter ended 30th June 2026.

Ref: Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 29 and 33 of the Listing Regulations 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday, 29th July 2026 to approve the following.

1. To consider, approve and take on record the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June 2026.
2. To transact any other business with the permission of the Chair.

The Company has already closed its "Trading Window" under the Code of Conduct for Prevention of Insider Trading with effect from 30th June, 2026, and the Trading Window shall remain closed until 48 hours after the declaration of the financial results. Accordingly, it shall re-open on 01st August, 2026.

You are requested to take note of the above.

Thanking You.

Yours faithfully,
For Nath Bio-Genes (India) Limited,

Amol Gupta
Chief Financial Officer